These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22938555)

  • 1. Hyperglycosylation prolongs the circulation of coagulation factor IX.
    Bolt G; Bjelke JR; Hermit MB; Hansen L; Karpf DM; Kristensen C
    J Thromb Haemost; 2012 Nov; 10(11):2397-8. PubMed ID: 22938555
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant coagulation factor IX: glycosylation analysis and in vitro conversion into human-like sialylation pattern.
    Fischer BE; Dorner F
    Thromb Res; 1998 Feb; 89(3):147-50. PubMed ID: 9622043
    [No Abstract]   [Full Text] [Related]  

  • 3. Pioneering designs for recombinant coagulation factors.
    Schulte S
    Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.
    Sehgal A; Barros S; Ivanciu L; Cooley B; Qin J; Racie T; Hettinger J; Carioto M; Jiang Y; Brodsky J; Prabhala H; Zhang X; Attarwala H; Hutabarat R; Foster D; Milstein S; Charisse K; Kuchimanchi S; Maier MA; Nechev L; Kandasamy P; Kel'in AV; Nair JK; Rajeev KG; Manoharan M; Meyers R; Sorensen B; Simon AR; Dargaud Y; Negrier C; Camire RM; Akinc A
    Nat Med; 2015 May; 21(5):492-7. PubMed ID: 25849132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium content in products used to treat haemophilia.
    Altisent C; Martorell M; de la Sierra A
    Haemophilia; 2016 Jul; 22(4):e324-7. PubMed ID: 27228069
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular approaches for improved clotting factors for hemophilia.
    Kaufman RJ; Powell JS
    Blood; 2013 Nov; 122(22):3568-74. PubMed ID: 24065241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.
    Østergaard H; Bjelke JR; Hansen L; Petersen LC; Pedersen AA; Elm T; Møller F; Hermit MB; Holm PK; Krogh TN; Petersen JM; Ezban M; Sørensen BB; Andersen MD; Agersø H; Ahmadian H; Balling KW; Christiansen ML; Knobe K; Nichols TC; Bjørn SE; Tranholm M
    Blood; 2011 Aug; 118(8):2333-41. PubMed ID: 21700771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm.
    Hamaguchi N; Roberts H; Stafford DW
    Biochemistry; 1993 Jun; 32(25):6324-9. PubMed ID: 8518277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hemophilias--from royal genes to gene therapy.
    Mannucci PM; Tuddenham EG
    N Engl J Med; 2001 Jun; 344(23):1773-9. PubMed ID: 11396445
    [No Abstract]   [Full Text] [Related]  

  • 10. Charge analysis of N-glycans from human recombinant coagulation factor VIII and human FVIII standards.
    Schilow WF; Schoerner-Burkhardt E; Seitz R
    Thromb Haemost; 2004 Aug; 92(2):427-8. PubMed ID: 15269842
    [No Abstract]   [Full Text] [Related]  

  • 11. [New formulation of recombinant coagulation factor: simplicity, rapidity and manageability].
    Fabregas B
    Soins; 2008 May; (725):22-3. PubMed ID: 18630084
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression and characterization of human factor IX. Factor IXthr-397 and factor IXval-397.
    Hamaguchi N; Charifson PS; Pedersen LG; Brayer GD; Smith KJ; Stafford DW
    J Biol Chem; 1991 Aug; 266(23):15213-20. PubMed ID: 1907972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk.
    Gil GC; Velander WH; Van Cott KE
    Glycobiology; 2008 Jul; 18(7):526-39. PubMed ID: 18456721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular genetics of hemophilia.
    Lawn RM; Vehar GA
    Sci Am; 1986 Mar; 254(3):48-54. PubMed ID: 3006240
    [No Abstract]   [Full Text] [Related]  

  • 16. In silico designing of hyper-glycosylated analogs for the human coagulation factor IX.
    Ghasemi F; Zomorodipour A; Karkhane AA; Khorramizadeh MR
    J Mol Graph Model; 2016 Jul; 68():39-47. PubMed ID: 27356208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mosaicism and female-to-female transmission in a kindred with hemophilia B (factor IX deficiency).
    Taylor SA; Deugau KV; Lillicrap DP
    Proc Natl Acad Sci U S A; 1991 Jan; 88(1):39-42. PubMed ID: 1986380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemophilia B (Factor IX Deficiency).
    Sidonio RF; Malec L
    Hematol Oncol Clin North Am; 2021 Dec; 35(6):1143-1155. PubMed ID: 34607716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.
    Shapiro A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1287-97. PubMed ID: 23930915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvements in factor concentrates.
    Lillicrap D
    Curr Opin Hematol; 2010 Sep; 17(5):393-7. PubMed ID: 20613509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.